At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 17 enrolled
Drug / intervention
Omalizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Predicting the Clinical Response to Omalizumab With Anti-IgE Response or Syk Expression in Basophils
In Brief
A Phase 4 clinical trial evaluating Omalizumab for Allergic Asthma. Completed, enrolled 17 participants across 1 site.
Detailed Summary
This research is being done to test whether differences in blood cells at baseline (start of the study) can be used to predict how well omalizumab will work in a patient. Omalizumab (Xolair) is a drug approved by the U.S. Food and Drug Administration (FDA) to treat asthma. Studies show that omalizumab improves the symptoms of asthma but some people experience better improvement than others.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Asthma
CountriesUnited States
CollaboratorsNovartis Pharmaceuticals
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2013
First PostedDec 2013
Primary CompletionJun 2016
Study CompletionAug 2016
TodayJul 2026
First PostedDec 30, 2013
Enrollment StartFeb 1, 2013
Primary CompletionJun 1, 2016
Study CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 12.5 years ago
Interventions
Omalizumabdrug